Ryo Inada

Dr. Ryo Inada


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2015 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
YMYoshiko Mori
Yoshiko Mori
TNTakeshi Nagasaka
Takeshi Nagasaka
HMHideyuki Mishima
Hideyuki Mishima
YUYuzo Umeda
Yuzo Umeda
RIRyo Inada
Ryo Inada
TFToshiyoshi Fujiwara
Toshiyoshi Fujiwara
The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients. Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600–601E, which has analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a prognostic marker for colorectal cancer (CRC). The present 65-year-old male patient was diagnosed with recurrent rectal adenocarcinoma (stage II by AJCC TNM staging 7th edition) 14 months after surgery and was treated with modified FOLFOX6 (fluorouracil, leucovorin, and oxaliplatin), radiation, and FOLFIRI (fluorouracil, leucovorin, and irinotecan). The tumor progressed before further treatment could be initiated, resulting in death after 15 months. This survival period was similar to the median overall survival among patients with metastatic CRC and BRAF mutations who were treated with the FOLFIRI regimen with or without cetuximab. Thus, the BRAF VK600–601E mutation may lead to an aggressive clinical course in CRC patients suffering from rapid progression and potential resistance to multiple therapeutic modalities.

14 May 2013 in Surgery Today
Verified
Journal Article
Closed access
PDF file
RIRyo Inada
Ryo Inada
SYSeiichiro Yamamoto
Seiichiro Yamamoto
TOTaihei Oshiro
Taihei Oshiro
MTMasashi Takawa
Masashi Takawa
SFShin Fujita
Shin Fujita
TATakayuki Akasu
Takayuki Akasu

22 October 2024 in Annals of Surgery
Verified
Journal Article
Open access
MNMasakatsu Numata
Masakatsu Numata
TYTomohiro Yamaguchi
Tomohiro Yamaguchi
ASAkio Shiomi
Akio Shiomi
RIRyo Inada
Ryo Inada
MSManabu Shiozawa
Manabu Shiozawa
LSLANDMARC Collaborative Study Group of the Japan Society of Laparoscopic Colorectal Surgery
LANDMARC Collaborative Study Group of the Japan Society of Laparoscopic Colorectal Surgery
Objective: To investigate the incidence of male sexual dysfunction including erectile dysfunction (ErD) and ejaculatory dysfunction (EjD) after minimally invasive rectal cancer surgery. Background: Male sexual dysfunction significantly affects after rectal cancer surgery quality of life. Current assessments using the International Index of Erectile Function-5 are unsuitable for patients with reduced postoperative sexual activity because it assume sexual intercourse. This study addresses this gap using the Erection Hardness Score and custom ejaculatory questionnaires. Methods: This prospective multicenter open-label phase 2 trial enrolled 399 patients who underwent laparoscopic (Lap), robotic (Ro), or transanal (Ta) rectal cancer surgery. Erection Hardness Score and custom ejaculatory questionnaires assessed ErD, EjD, and potency impairment at 3, 6, and 12 months postoperatively. The rates were assessed in the full analysis set and compared between the Lap and Ro groups after propensity score matching. Results: At 12 months, the overall incidences of ErD and EjD were 34.7% and 29.8%, respectively. The Ro group showed a significantly lower EjD rate (25.0%) than the Lap group (40.9%), with no significant difference in ErD. Potency impairment was lower in the Ro group at 6 months (32.7% vs 22.3%) and 12 months (29.0% vs 17.8%) postoperatively. The Ta group showed relatively high ErD and EjD at 3 months, with some recovery at 12 months. Conclusions: Minimally invasive rectal cancer surgery commonly results in ErD, EjD, and potency impairment. Ro surgery provides lower EjD rates and less potency impairment. Comprehensive sexual function assessments are essential to inform patients and improve quality of life outcomes.

16 July 2022 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
TATomonori Akagi
Tomonori Akagi
KNKentaro Nakajima
Kentaro Nakajima
YHYasumitsu Hirano
Yasumitsu Hirano
TATomoya Abe
Tomoya Abe
RIRyo Inada
Ryo Inada
TSThe Japan Society Of Laparoscopic Colorectal Surgery
The Japan Society Of Laparoscopic Colorectal Surgery
Aim: Whether a laparoscopic procedure can contribute to the improvement of clinical outcomes in obese patients with stage II/III rectal cancer compared to an open procedure remains unclear.Objective: This study evaluated the technical and oncological safety of laparoscopic surgery versus open surgery in obese patients (body mass index [BMI] ≥25 kg/m2) with rectal cancer.Patients and Methods: Data were collected from patients with pathological stage II/III rectal cancer and analyzed. Operations were performed via laparoscopic or open surgery from 2009 to 2013. A comparative analysis was performed after applying propensity score matching to the two cohorts (laparoscopic group and open group). The primary endpoint was 3‐y relapse‐free survival (RFS).Results: Overall, 524 eligible cases were collected from 51 institutions. Equal numbers of propensity score‐matched patients were included in the laparoscopic (n = 193) group and open (n = 193) group. Although the rate of D3 lymph node dissection did not differ between the laparoscopic group (87.0%) and the open group (88.6%), the median number of harvested lymph nodes was significantly lower in the laparoscopic group versus open group (17.5 vs 21, P = 0.0047). The median postoperative hospital stay was also significantly shorter in the laparoscopic group (14 d) vs the open group (17 d) (P = 0.0014). Three‐y RFS was not significantly different between the two groups (hazard ratio 1.2454, 95% confidence interval 0.9201–1.6884, P = 0.4689).Conclusion: The short‐ and long‐term results of this large cohort study (UMIN ID: UMIN000033529) indicated that laparoscopic surgery in obese rectal cancer patients has advantageous short‐term outcomes and no disadvantageous long‐term outcomes.

8 December 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
TMTatsuya Morikawa
Tatsuya Morikawa
RIRyo Inada
Ryo Inada
TNTakeshi Nagasaka
Takeshi Nagasaka
YMYoshiko Mori
Yoshiko Mori
HKHiroyuki Kishimoto
Hiroyuki Kishimoto
TFToshiyoshi Fujiwara
Toshiyoshi Fujiwara
In stage IV colorectal cancer (CRC), initial resection of the primary tumor is considered to be an important strategy for improving disease outcome. However, there is no consensus on the timing as to when the surgical intervention of the primary tumor should occur. The present study hypothesizes that genetic profiles in CRC may indicate the appropriate treatment strategies for patients with stage IV CRC, and a cohort of 113 patients with stage IV CRC resected primary lesions at various periods were analyzed for the presence of mutations in the KRAS, exon 2, and BRAF genes, exon 15, and for the microsatellite instability status of the tumor. These data were additionally correlated with various clinicopathological features. Although BRAF‑mutant was revealed to be an independent negative prognostic factor in stage IV CRC (HR, 8.42; 95% confidence interval, 2.72‑26.02), BRAF‑mutant samples exhibited better prognoses if they were treated with chemotherapy prior to tumor resection. Thus, the presence of BRAF mutations provides a compelling rationale for the establishment of intensive upfront chemotherapy to improve survival in stage IV CRC.

12 May 2022 in European Journal of Cancer
Verified
Journal Article
Open access
RIRyo Inada
Ryo Inada
TNTakeshi Nagasaka
Takeshi Nagasaka
MSMototsugu Shimokawa
Mototsugu Shimokawa
HOHitoshi Ojima
Hitoshi Ojima
SNShingo Noura
Shingo Noura
YYYoshiyuki Yamaguchi
Yoshiyuki Yamaguchi
An optimal treatment strategy using oxaliplatin and bevacizumab for metastatic colorectal cancer has not been defined. We investigated whether the sequential treatment using fluoropyrimidines with bevacizumab followed by the addition of oxaliplatin at first progression was better than a combination treatment using fluoropyrimidines and oxaliplatin with bevacizumab. In the sequential treatment, the escalation from fluoropyrimidines plus bevacizumab to fluoropyrimidines plus oxaliplatin with bevacizumab was recommended in case of progressive disease. Time to failure of strategy was the primary end-point, whereas the secondary end-points were overall survival, progression-free survival, overall response rate and safety. Three hundred patients with previously untreated metastatic colorectal cancer were randomised to receive either the sequential treatment (n = 151) or the combination treatment (n = 149). The sequential treatment was superior to the combination treatment about time to failure of strategy (15.2 months; 95% CI, 12.5-17.2 months vs. 7.8 months: 95% CI, 6.3-9.5 months; P < 0.001). However, the median overall survival was 27.5 (95% CI, 24.4 to 32.7) months in the sequential treatment and 27.0 (95% CI, 22.8 to 36.0) months in the combination treatment (hazard ratio, 0.92; 95% CI, 0.66 to 1.28; P = 0.61). The overall response rate was 33.1% in the sequential treatment arm and 51.7% in the combination treatment. The findings support the extension of the sequential treatment starting from fluoropyrimidine plus bevacizumab to selected patients who do not need an objective response to the threatening disease.